8-K: Alkermes Reports Strong 2023 Results and Sets Optimistic 2024 Financial Targets

Alkermes reported a profitable 2023 with significant revenue growth and provided positive financial expectations for 2024, driven by its focus on neuroscience.

Summary

• Alkermes announced its financial results for the fourth quarter and full year of 2023, along with financial expectations for 2024.
• The company reported total revenues of $1.66 billion in 2023, with a notable 18% year-over-year increase in net sales of proprietary products.
• GAAP net income for 2023 was $356 million, resulting in diluted GAAP earnings per share of $2.10.
• Alkermes expects to achieve a 30% EBITDA margin in 2024.
• LYBALVI revenues saw substantial growth, with a 61% increase in the fourth quarter and a 100% increase for the full year compared to 2022.
• The company's cash, cash equivalents, and total investments stood at $813.4 million as of December 31, 2023.
• A new share repurchase program was approved, authorizing up to $400 million in share repurchases.
• For 2024, Alkermes anticipates total revenues between $1.5 billion and $1.6 billion, with GAAP net income between $350 million and $390 million.
• The company expects VIVITROL net sales between $410 million and $430 million, ARISTADA net sales between $340 million and $360 million, and LYBALVI net sales between $275 million and $295 million in 2024.
• Alkermes completed the separation of its oncology business into Mural Oncology plc in November 2023.
• The company also entered into an agreement to sell its Athlone, Ireland facility to Novo Nordisk for $92.5 million, expected to close in mid-2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, significant growth in key products, and optimistic future guidance. The company's strategic moves and focus on neuroscience are also viewed favorably.

Positives

• Alkermes demonstrated strong financial performance in 2023, with significant revenue growth and profitability.
• The company's proprietary products, particularly LYBALVI, showed substantial sales growth.
• The successful resolution of the Janssen arbitration resulted in a significant boost to royalty revenues.
• The new share repurchase program indicates confidence in the company's future prospects.
• The divestiture of the oncology business and the sale of the Athlone facility will allow Alkermes to focus on its core neuroscience business.
• The company has a strong cash position, providing financial flexibility.
• Alkermes is advancing its pipeline, including the ALKS 2680 program for narcolepsy.

Negatives

• The company's total revenue guidance for 2024 is lower than the 2023 actual revenue, reflecting the expiration of a royalty agreement.
• The company experienced a loss from discontinued operations related to the separated oncology business.
• SG&A expenses increased due to investments in LYBALVI advertising and legal settlements.

Risks

• The company's ability to sustain profitability is subject to various risks and uncertainties.
• Unfavorable outcomes in arbitration or litigation could negatively impact the company.
• Clinical development activities may not be completed on time or may not yield positive results.
• Regulatory authorities may not agree with the company's approval strategies or may make adverse decisions regarding its products.
• The company and its licensees may not be able to continue to successfully commercialize their products.
• There may be a reduction in payment rates or reimbursement for the company's products.
• The company's products may prove difficult to manufacture or have unintended side effects.

Future Outlook

Alkermes anticipates continued growth in its proprietary product sales, particularly LYBALVI, and expects to generate significant cash flow and sustain profitability in 2024. The company plans to advance its neuroscience pipeline and explore external opportunities to expand its portfolio. They also plan to return excess cash to shareholders.

Management Comments

• Richard Pops, Chief Executive Officer of Alkermes, stated that the company is well positioned to deliver on its strategic priorities to drive growth of proprietary commercial products, advance the clinical development of ALKS 2680, and generate significant cash flow.
• Management believes that 2024 will be an important year as they focus on maintaining strong momentum in the launch of LYBALVI and advancing their development pipeline.

Industry Context

This announcement reflects a broader trend in the pharmaceutical industry where companies are focusing on core therapeutic areas and divesting non-core assets to improve profitability and growth. Alkermes' focus on neuroscience aligns with the increasing demand for treatments in this area. The company's performance is also being viewed in the context of the competitive landscape for treatments for schizophrenia, bipolar disorder, and addiction.

Comparison to Industry Standards

• Alkermes' 18% year-over-year growth in proprietary product sales is strong compared to the average growth rate of many established pharmaceutical companies, which often see single-digit growth.
• The 30% EBITDA margin target for 2024 is competitive with other profitable biopharmaceutical companies, such as Vertex Pharmaceuticals, which has a similar focus on specialty markets.
• The growth of LYBALVI is particularly notable, as it is outpacing the growth of many other antipsychotic medications in the market, such as those from Johnson & Johnson, which Alkermes partners with on other products.
• The share repurchase program is a common practice among companies with strong cash flow, similar to what is seen with companies like Amgen and Gilead Sciences.
• The divestiture of the oncology business is a strategic move similar to what other companies like Pfizer have done to focus on core therapeutic areas.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the company's focus on profitability and growth.
• Employees will be impacted by the company's strategic shift towards neuroscience and the divestiture of the oncology business.
• Customers will benefit from the continued availability of Alkermes' products and the development of new treatments.
• Suppliers and creditors will be impacted by the company's financial performance and strategic decisions.

Next Steps

• Alkermes plans to initiate a phase 2 program for ALKS 2680.
• The company will continue to advance its internal development candidates and explore external pipeline opportunities.
• Alkermes will focus on delivering strong commercial growth and profitability.
• The company will continue to focus on capital allocation, including potential opportunities to return capital to shareholders.
• The sale of the Athlone facility is expected to close in mid-2024.

Key Dates

Keywords

Alkermes, Neuroscience, LYBALVI, VIVITROL, ARISTADA, Financial Results, EBITDA, Share Repurchase, ALKS 2680, Pharmaceuticals, Biotechnology